Compare CLWT & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLWT | CMMB |
|---|---|---|
| Founded | 1971 | 2004 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Professional and commerical equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 11.1M |
| IPO Year | 1996 | 2023 |
| Metric | CLWT | CMMB |
|---|---|---|
| Price | $1.60 | $1.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 85.1K | ★ 233.7K |
| Earning Date | 05-12-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $17.56 | $34.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $0.87 |
| 52 Week High | $2.68 | $3.86 |
| Indicator | CLWT | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 49.37 | 42.32 |
| Support Level | $1.10 | N/A |
| Resistance Level | $1.58 | $1.89 |
| Average True Range (ATR) | 0.12 | 0.17 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 30.96 | 7.55 |
Euro Tech Holdings Co Ltd is mainly a distributor of a wide range of water treatment equipment, laboratory instruments, analyzers, test kits, and related supplies, and power generation equipment, including recorders and power quality analyzers. The Company acts as an exclusive or non-exclusive distributor for manufacturers of such equipment to commercial customers and governmental agencies in Hong Kong and mainland China, as well as commercial customers in Macau. It has two operating segments: Trading and manufacturing, which generate maximum revenue and act as a distributor of water treatment equipment, laboratory instruments, analyzers, test kits, related supplies, and power generation equipment; and the Engineering segment. The Company generates maximum revenue from the PRC.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.